Clinical Trials Logo

Inborn Errors of Metabolism clinical trials

View clinical trials related to Inborn Errors of Metabolism.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03866954 Withdrawn - Metabolic Disease Clinical Trials

Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy

TEETPIM
Start date: November 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, action and effectiveness of repeated doses of Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP) for the treatment of patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). MNGIE is a rare inherited disease that mainly affects the digestive and nervous system and is caused by a defect in the function of an enzyme called thymidine phosphorylase. This loss of function causes certain molecules (thymidine and deoxyuridine) to accumulate in cells which leads to toxic damage to these cells. The disease can be confirmed by detecting variations (mutations) in the thymidine phosphorylase gene (TYMP). Currently there are no specific treatments for patients with MNGIE, whose effectiveness has been shown through clinical trials. The potential treatment for MNGIE offered in this trial is an enzyme replacement therapy, i.e. replacing functional thymidine phosphorylase. This treatment uses the patients own red blood cells in which thymidine phosphorylase is encapsulated to produce EE-TP (the study drug). EE-TP is created using a machine named a Red Cell Loader (RCL) and is then administered back to the patient.

NCT ID: NCT01341379 Withdrawn - Clinical trials for Inborn Errors of Metabolism

Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate

Start date: December 2010
Phase: Phase 2
Study type: Interventional

Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors of metabolism. The investigators propose to determine if short-term (3 day) treatment with N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients. The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators would consider more extensive long-term studies of the drug.

NCT ID: NCT01003912 Withdrawn - Clinical trials for Inborn Errors of Metabolism

Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases

IUHST-001
Start date: October 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if it is safe to administer unrelated umbilical cord blood to pregnant women in their first trimester of pregnancy with a fetus that has a known diagnosis of certain lysosomal storage diseases. These diseases are known to cause severe and irreversible neurological disability in early infancy and which are lethal in childhood.